441 related articles for article (PubMed ID: 22945919)
1. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
[TBL] [Abstract][Full Text] [Related]
2. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
3. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
[TBL] [Abstract][Full Text] [Related]
4. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
[TBL] [Abstract][Full Text] [Related]
5. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
6. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo.
Legrand N; Huntington ND; Nagasawa M; Bakker AQ; Schotte R; Strick-Marchand H; de Geus SJ; Pouw SM; Böhne M; Voordouw A; Weijer K; Di Santo JP; Spits H
Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13224-9. PubMed ID: 21788504
[TBL] [Abstract][Full Text] [Related]
7. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
8. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
9. Human CD47 expression permits survival of porcine cells in immunodeficient mice that express SIRPα capable of binding to human CD47.
Wang C; Wang H; Ide K; Wang Y; Van Rooijen N; Ohdan H; Yang YG
Cell Transplant; 2011; 20(11-12):1915-20. PubMed ID: 21535911
[TBL] [Abstract][Full Text] [Related]
10. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
11. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
12. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
13. Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.
Irandoust M; Alvarez Zarate J; Hubeek I; van Beek EM; Schornagel K; Broekhuizen AJ; Akyuz M; van de Loosdrecht AA; Delwel R; Valk PJ; Sonneveld E; Kearns P; Creutzig U; Reinhardt D; de Bont ES; Coenen EA; van den Heuvel-Eibrink MM; Zwaan CM; Kaspers GJ; Cloos J; van den Berg TK
PLoS One; 2013; 8(1):e52143. PubMed ID: 23320069
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
15. The CD47-SIRPα signalling system: its physiological roles and therapeutic application.
Murata Y; Kotani T; Ohnishi H; Matozaki T
J Biochem; 2014 Jun; 155(6):335-44. PubMed ID: 24627525
[TBL] [Abstract][Full Text] [Related]
16. Anti-SIRP
Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
[TBL] [Abstract][Full Text] [Related]
17. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages.
Ide K; Wang H; Tahara H; Liu J; Wang X; Asahara T; Sykes M; Yang YG; Ohdan H
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5062-6. PubMed ID: 17360380
[TBL] [Abstract][Full Text] [Related]
18. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
19. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
20. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
